Pharma major Lupin on Monday said it has launched generic Fosaprepitant injection, used to prevent nausea and vomiting associated with cancer chemotherapy in adults, in the American market. The company has launched Fosaprepitant for injection, 150 mg single-dose vial, having received an approval earlier for it from the United States Food and Drug Administration (USFDA), Lupin said in a filing to the BSE.The product is a generic version of Merck Sharp & Dohme Corp's Emend for injection in the same strength, it added.According to IQVIA MAT July 2020 data, Fosaprepitant for injection, 150 mg single-dose vial, had annual sales of approximately USD 136 million (about Rs 1,000 crore) in the US, Lupin said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!